Patrizio Pasquale, Darmon Sarah, Barad David H, Gleicher Norbert
Chief Division Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami, Miller School of Medicine, Don Soffer CRC-1120 NW 14Th Street, Suite 1150, Miami, FL, 33176, USA.
The Center for Human Reproduction, New York, NY, USA.
J Assist Reprod Genet. 2025 Jan;42(1):81-84. doi: 10.1007/s10815-024-03340-1. Epub 2024 Dec 7.
This study aims to assess whether increased utilization for preimplantation genetic testing for aneuploidy (PGT-A) relates to improved live birth rates in IVF and whether IVF clinic ownership relates to PGT-A utilization. In a retrospective cohort study involving > 90% of US IVF clinics reporting to the Center for Disease Control and Prevention (CDC), stratified for ages (< 35, 35-37, 38-40, 41-42, and ≥ 43 years), and with reference point cycle start, we investigated whether PGT-A utilization related to live birth rates and ownership format as either physician-, academic/hospital/military, or equity/venture capital (VC) owned clinics. The lowest PGT-A-utilizing clinics reported significantly better live birth rates than the highest-utilizing clinics. Youngest patients (under age 35) were most adversely affected by high PGT-A utilization. Clinic ownership, moreover, is significantly related to the utilization of PGT-A, with equity and/or venture capital (VC)-owned clinics being significantly overrepresented among high-utilizing clinics in comparison to clinics owned by private physicians or by academia, hospitals, and the military. PGT-A, overall, reduces live birth chances in IVF, with the risks of adverse outcome effects increasing with growing PGT-A utilization in primarily younger women under age 35. Equity/VC ownership favors increasing PGT-A utilization in comparison to private physician and academic/hospital/military clinic ownership. These findings suggest intervention strategies to reverse excessive PGT-A utilization.
本研究旨在评估非整倍体胚胎植入前遗传学检测(PGT-A)使用的增加是否与体外受精(IVF)活产率的提高相关,以及IVF诊所的所有权形式是否与PGT-A的使用相关。在一项回顾性队列研究中,纳入了向疾病控制与预防中心(CDC)报告的超过90%的美国IVF诊所,按年龄分层(<35岁、35 - 37岁、38 - 40岁、41 - 42岁和≥43岁),并以周期开始作为参考点,我们调查了PGT-A的使用与活产率以及所有权形式(医生所有、学术/医院/军队所有或股权/风险投资(VC)所有的诊所)之间的关系。PGT-A使用最少的诊所报告的活产率显著高于使用最多的诊所。最年轻的患者(35岁以下)受高PGT-A使用率的不利影响最大。此外,诊所所有权与PGT-A的使用显著相关,与私人医生或学术、医院及军队所有的诊所相比,股权和/或风险投资(VC)所有的诊所在高使用率诊所中所占比例显著过高。总体而言,PGT-A降低了IVF的活产几率,在主要为35岁以下的年轻女性中,随着PGT-A使用率的增加,不良结局影响的风险也在增加。与私人医生及学术/医院/军队所有的诊所相比,股权/VC所有的诊所更倾向于增加PGT-A的使用。这些发现提示了扭转PGT-A过度使用的干预策略。